Investors

Benzinga Virtual HealthCare Summit 2024

Email Alerts

Stay informed and receive company updates straight to your inbox

The press releases contained in this archive reflect information as of their original publication dates. AXIM Biotechnologies undertakes no obligation to update such information except as required by law.  Current information regarding the Company’s products and regulatory status is available on this website.

Recent News

AXIM Biotechnologies CEO Issues Letter to Shareholders

Summary: In 2022, AXIM® finalized optimization of its R&D and manufacturing infrastructure to be used in its diagnostic program AXIM will continue to generate revenue from its two FDA-cleared dry eye disease (DED) diagnostic tests through commercialization partner...

Latest Annual Filing

Fiscal Year Ended Dec 31, 2022